chrisvoncsefalvay/vaers-outcomes huggingface dataset:
she has 19 friends who lost their life because of the vaccine; This spontaneous report from a non-contactable reporter(s) (Consumer or other non HCP) Program ID: (Unknown) reporting same event under the same suspect product for 19 patients. This is one of 19 reports.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEATH (death), outcome "fatal", described as "she has 19 friends who lost their life because of the vaccine". The date and cause of death for the patient were unknown. It was not reported if an autopsy was performed.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201319230 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325359 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325360 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325361 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325362 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325363 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325364 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325365 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325366 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325367 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325368 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325369 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325370 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325371 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325372 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325373 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325374 Same reporter/vaccine/event, different patients;US-PFIZER INC-202201325375 Same reporter/vaccine/event, different patients;; Reported Cause(s) of Death: she has 19 friends who lost their life because of the vaccine
Got my booster on 12/29. Beginning 12/30 I developed a sore throat, congestion, coughing, runny nose and my heart rate was at 203. My HR later came down to 57 few minutes later. HR remains slightly elevated at rest around 103. All other symptoms are still ongoing as of today 1/1.
Arm pain; Migraine headache; Weak stomach; lack of energy; sleepiness; Foggy eyes; dizziness; Difficulty moving arm; lightheadedness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm pain), MIGRAINE (Migraine headache), ABDOMINAL DISCOMFORT (Weak stomach), ASTHENIA (lack of energy) and SOMNOLENCE (sleepiness) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Low platelets, Hemoglobin low and WBC abnormal (low). Concomitant products included PARACETAMOL (TYLENOL) and MELOXICAM for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, the patient experienced PAIN IN EXTREMITY (Arm pain), MIGRAINE (Migraine headache), ABDOMINAL DISCOMFORT (Weak stomach), ASTHENIA (lack of energy), SOMNOLENCE (sleepiness), VISION BLURRED (Foggy eyes), DIZZINESS (dizziness), LIMB DISCOMFORT (Difficulty moving arm) and DIZZINESS (lightheadedness). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Arm pain), MIGRAINE (Migraine headache), ABDOMINAL DISCOMFORT (Weak stomach), ASTHENIA (lack of energy), SOMNOLENCE (sleepiness), VISION BLURRED (Foggy eyes), DIZZINESS (dizziness), LIMB DISCOMFORT (Difficulty moving arm) and DIZZINESS (lightheadedness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's medical history included historical treatment with chemotherapy for an unknown indication.   Additional concomitant medications included chemotherapy and an unspecified allergy tablet for drug use for unknown indication.
Myalgia, Fever, c/o tingling under eyes and face,fatigue,sweating,injection pain,slight SOB. Told to follow up with primary care physician  Narrative:
fatigue, headache, body aches, joint aches, fever to 101 degrees, sweats, swollen lymph nodes left axilla
Breaking out in sores on elbows/Twice on right elbow, which went away, but now on the left elbow; This spontaneous case was reported by a patient and describes the occurrence of ARTHRALGIA (Breaking out in sores on elbows/Twice on right elbow, which went away, but now on the left elbow) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (Breaking out in sores on elbows/Twice on right elbow, which went away, but now on the left elbow). At the time of the report, ARTHRALGIA (Breaking out in sores on elbows/Twice on right elbow, which went away, but now on the left elbow) had not resolved.            No relevant concomitant medications were reported. Treatment medication was not provided by the reporter.   Reporter did not allow further contact
Ears started to feel pressure and pop almost immediately.  Popping sensation stopped within 90 minutes. Very mild pain in ears related to full feeling ears.
Worsening muscle/body aches, joint pains, general weakness, headaches, lightheadedness, loss of appetite, low-grade fever relieved by medication, groin pains
Initial report was received from a consumer on 16 July 2013. A 12-year-old male patient had received an injection of RABIES VACCINE (manufacturer, lot number, route, site and date of administration not reported) and an unspecified amount of time later experienced Guillain-Barre Syndrome (GBS). The reporter did not have any further information regarding the event as the patient was not in their practice at the time of vaccination. Outcome was reported as recovered. Documents held by sender: None.
only get the flu when I get the flu shot; Initial information received on 19-Oct-2023 regarding an unsolicited valid non-serious case received from a consumer/non-hcp (non-healthcare professional) via Social Media.  This case involves an unknown age and unknown gender patient who only get the flu when patient got the influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a  dose of suspect influenza vaccine produced by unknown manufacturer (strength, dosage, expiry date, formulation, lot number- not reported) via unknown route in unknown administration site for prophylactic vaccination (Immunisation).Information on the batch number was requested.  On an unknown date the patient only get the flu when patient got the flu shot (influenza) (unknown latency) following the administration of influenza vaccine.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event.  At time of reporting, the outcome was Unknown for the event.
I have been sick 3 times since the vaccine the 4th time I had covid in november of 2021
underage dose; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (underage dose) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (underage dose). On 25-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (underage dose) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.   Treatment information was not provided.   This case was linked to MOD-2021-086147 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 09-Jun-2021: Patient demographic details has been updated including race, ethnicity, height and weight.
Red, warm, itchy area left thigh. Treated with Benadryl/Augmentin.
Immunizations administered between 10 and 11 am on 9/12/07.  Grandmother reports hands and arms became blue and mottled around noon.  Caretaker also noted swelling of right lower extremity.  Thye transported infant to local hospital and was seen in the ER.  Infant was given Benadryl IM
Information has been received from a registered nurse for the pregnancy registry for GARDASIL concerning an 18 year old female with a history of chickenpox disease at age 5 and no allergies who on 25-APR-2008 was vaccinated with the first dose of GARDASIL 0.5 ml IM. The patient at the time of vaccination of the first dose indicated she was not pregnant. On approximately 09-MAY-2008, the patient found out she was pregnant. The patient started at an unspecified date and went to the hospital. The hospital informed her on 01-JUN-2008 the patient had a miscarriage. On 25-JUL-2008 the patient was vaccinated with the second dose of GARDASIL 0.5 ml IM. The patient sought medical attention and told the nurse at an office visit. Upon internal review, miscarriage was determined to be an other important medical event. Additional information has been requested
wheel and flare at vaccination site; Initial information was received on 28-Sep-2020 regarding an unsolicited valid non-serious case from a physician.  This case is linked to case 2020SA267990 (same reporter)  This case involves a patient (gender unspecified) who had a wheel and flare at injection site (vaccination site urticaria), when received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  Medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot number not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious wheel and flare at injection site (vaccination site urticaria) within the last few weeks following the administration of INFLUENZA QUADRIVAL A-B VACCINE.  No laboratory data was provided.   It was not reported if the patient received a corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on lot number.
It started with a tingling feeling above my right knee.  After a few days, my whole quad was tingling/numb.  My calf then felt like it wanted to cramp up, but never did.  My root foot then became tingly/numb.  After a month, parts of my leg continue to feel tingly and numb.  I do have strength and range of motion.
Initial unsolicited report received from a health care professional on 03-Oct-2016. This case involves a 80-year-old male patient, who was vaccinated with FLUZONE HD (batch number: UI666AA , expiry date: 13-Apr-2017) via intramuscular route (dose and dose in series not reported) in leg on 28-Sep-2016. Patient's Illness at time of vaccination and pre-existing physician diagnosed allergies, birth defects, medical conditions were reported as DM Type II (diabetes mellitus II ), HTN (hypertension). It was also unknown that patient received any other vaccines within four week of suspect vaccine. Concomitant medications were not reported. On 28-Sep-2016, same day following the vaccination, the patient had shaking chills with accompanied abdominal pain. Lab test and corrective treatment was not reported. Patient recovered from abdominal pain on the same day after approximately two hours and chills by the next day. Documents held by sender: none.
Subject in pneumococcal vaccine trial, with severe COPD, was hospitalized for worsening interstitial cystisis. Vaccination took place on 7/28/2008. According to the physician the relationship is 'None'. We would be happy to forward the Study's SAE reporting form upon request.  3/26/09 MR received from reporter for DOS 3/3-4/2009 with D/C DX:  Interstitial Cystitis-worsened. Pt presented with recent flare of IC with suprapubic pressure and pain.  Pt underwent cystoscopy and biopsies with bladder distention.  Foley placed for med insertion.  Voiding OK on POD#1 and d/c.
Injection site: redness, soreness, hives, rash. Systemic: general malaise, fatigue, loss of appetite for 24 hours. GI: sever stomach ache, cramps and loose stools.
I found out that my cancer returned.  I have metatstic cnacer.  This was not an adverse reaction to the vaccine.
CLIENT RECEIVED PEDIATRIC PFIZER FORMULATION OF 0.2ML AT 12YO. CLIENT SHOULD HAVE RECEIVED THE GRAY CAP FORMULATION OF 0.3ML DUE TO AGE.
This spontaneous report was received from a registered nurse and refers to a 13 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 14-AUG-2017, the patient was vaccinated with an improperly stored VARIVAX at a dose of 0.5 (units not specified) from lot # N000683 with expiry date: 06-JAN-2019 (dose number, route, anatomical location and site of administration were not reported) for prophylaxis. Concomitant medications included a properly stored sterile diluent (manufacturer unknown). The administered dose of vaccine was stored in the temperature between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 20 hours and in the temperature between 15 degrees Fahrenheit and 46 degrees Fahrenheit for 6 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No additional information was provided. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1707USA004945.
This case was reported by a nurse via call center representative and described the occurrence of fever in a adult female patient who received FLUARIX QUADRIVALENT (batch number AF29T, expiry date 25th June 2017). Concomitant products included PNEUMOVAX. On 24th September 2016, the patient received FLUARIX QUADRIVALENT .5 ml. On 25th September 2016, 1 days after receiving FLUARIX QUADRIVALENT, the patient experienced fever and general body pain. On an unknown date, the patient experienced pharmaceutical product complaint. In September 2016, the outcome of the fever and general body pain were recovered/resolved. On an unknown date, the outcome of the pharmaceutical product complaint was unknown. The reporter considered the fever and general body pain to be related to FLUARIX QUADRIVALENT. Additional details were provided as follows: This case was previously reported to a doctor. The age at vaccination was not reported. The patient reported that she experienced fever and body aches after receiving FLUARIX QUADRIVALENT in her right deltoid. On the same day, the patient received PNEUMOVAX vaccine concomitantly. The nurse reported that vaccine was given to 3 health care providers. She insisted AF29T particular batch of vaccine was defective and this batch was producing adverse symptoms, which were not experienced in previous year's vaccines. She was unable to credit per content. This is on of the 3 cases reported by the same reporter.
Headache  4:00 Body ache 6:00 Nausea 6:00
Pt presented to my office on 4/30 after being vaccinated on 4/20 with left arm swelling. Outpatient stat DVT study in LUE showed extensive thrombosis in veins of LUE and subobcclusive thrombosis in BL Internal Jugular veins. I referred pt to hospital for inpatient admission.
Hives; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of URTICARIA (Hives) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced URTICARIA (Hives). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL ALLERGY [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, URTICARIA (Hives) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
chills; muscle aches; HEADACHE; This case was reported by a consumer via call center representative and described the occurrence of chills in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 27th October 2020, the patient received the 1st dose of Shingrix. On 28th October 2020, 1 days after receiving Shingrix, the patient experienced chills, muscle pain and headache. On an unknown date, the outcome of the chills, muscle pain and headache were not recovered/not resolved.   It was unknown if the reporter considered the chills, muscle pain and headache to be related to Shingrix.  Additional details were provided as follows: The age group was not reported, however it was captured as an adult as per vaccine indication. The age at vaccination was not reported. The patient enquired that how long did the Shingrix side effects lasted. The patient got the first injection of Shingrix a day before reporting and on the day of reporting was experiencing muscle aches, chills and headache. The patient was just wondering how long this would last, 2 -3 days. The patient enquired if they could take Advil or Tylenol to address these symptoms.
pt recvd 3 doses of Engerix-B on 23OCT90; 20NOV90 & 23APR91; AUG91 HEp B surface antibody was neg;
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On 03-DEC-2010, the patient was inoculated with ZOSTAVAX by a healthcare provider to obtain permanent prevention and protection against shingles and zoster-related injuries (dose, route, and lot # not provided). In 2016, the patient was treated by a healthcare provider for herpes zoster. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the had and would continue suffered ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered as not recovered. Causality assessment was related.
Breakthrough COVID 19 infection resulting in  hospitalization.  Hospitalized 3/7/2022
Lack of sleep; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 24Feb2021 at 14:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history not reported. Concomitant medication included chemotherapy from an unknown date, for unknown indication and unknown if ongoing. The patient had no known allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Feb2021 at 23:00, the patient experienced lack of sleep. On an unknown date, the patient underwent SARS Cov2 test (nasal swab test) and the result was unknown. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported event. The clinical outcome of the event lack of sleep was recovered on an unknown date in 2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.
Headache, Myalgia, Fever, Paresthesia left arm, leg, face and neck Narrative:
Enlargement of the spinal cord suspected; Tachycardia; Paresthesia; Burning feeling in the head/face; This is a spontaneous report from a non-contactable consumer (patient) based on information received by Pfizer from Moderna (MDCH21-00500). This consumer reported similar events for two patients. This is the second of two reports.   A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose number unknown, via an unspecified route of administration on an unspecified date (Batch/Lot number unknown) as a single dose for COVID-19 immunisation. Medical history was not reported. There were no concomitant medications. On an unknown date (after the vaccination), this patient experienced tachycardia, paresthesia and burning feeling in the head/face. This patient attended a medical examination where he met another patient who experienced the same events after the vaccination and these symptoms were caused by an enlargement of the spinal cord. It was reported that they probably were both affected by the same condition (enlargement of the spinal cord). The outcome of the events suspected enlargement of the spinal cord, tachycardia, paresthesia and burning feeling in the head/face was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : PFIZER INC-202101440896 same reporter/AE/SD, different patient
PT recd Engerix-B on 30OCT90, 1JAN91, & 11JUN91; w/in 36hrs of 3rd dose became tired w/weakness; 50hrs later severity of symptoms inc & dev fever, chills, sweating, & severe h/a; to ER & rx w/Motrin (600mg PO); PT was alert; LFTs abnormal
Chills Hot flashes Oversensitive to touch Fatigue Decreased appetite Balance problems Pain at injection site
Pt became shaky and nauseuos within a few minutes.  She got 3 hives.  BP 125/65 pulse 93, No wheezing or trouble breathing.  25 mg of benadryl was given po.  She drank 1/2 of a can of gatorade and ate a few graham crackers.  After 25 minutes she stated she felt fine and was sent home with a script for benadryl 50 mgm to be taken every 6-8 hours. She still had the hives but there were no more.  She was advised to call EMS if any trouble breathing
PATIENT STATED SHE HAD AN EXACERBATION OF HER POSTHERPETIC NEURALGIA DAY AFTER RECIEVING VACCINE ON THE RIGHT SIDE OF HER BODY
Guillian-Barre Syndrome diagnosed 12/7/10. Very weak both arms/numb also. Started 12/4/10. Treated at hospital.